Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s share price hit a new 52-week high during trading on Monday . The company traded as high as $15.31 and last traded at $15.12, with a volume of 2903073 shares traded. The stock had previously closed at $15.16.
Takeda Pharmaceutical Price Performance
The company has a market cap of $47.71 billion, a price-to-earnings ratio of 37.49, a PEG ratio of 0.24 and a beta of 0.46. The company's 50 day moving average price is $14.04 and its 200 day moving average price is $13.91. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.
Institutional Investors Weigh In On Takeda Pharmaceutical
Several institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at about $26,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Takeda Pharmaceutical during the 3rd quarter valued at approximately $40,000. BNP Paribas Financial Markets lifted its position in shares of Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Takeda Pharmaceutical in the 3rd quarter valued at approximately $52,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
